Isofol Medical (ISOFOL.ST) Stock Analysis & AI Equity Report
Isofol Medical (ISOFOL.ST) overview
Isofol Medical (ISOFOL.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Isofol Medical reported revenue of SEK 0m and operating profit of SEK -47.2m; the year-end share price was 2.22 SEK and market capitalisation was SEK 358m. Isofol Medical is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Isofol Medical's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Isofol Medical
Isofol Medical AB is a clinical-stage biotechnology company focused on developing arfolitixorin, a drug candidate designed to improve the effect of standard chemotherapy for patients with severe forms of cancer. Its current development work centers on metastatic colorectal cancer, and the company’s value driver is advancing this oncology program through clinical testing and regulatory progress.
Generate the Isofol Medical report
Isofol Medical is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Isofol Medical and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.